U sing gene therapy to treat human cancers is currently hampered by the lack of efficient delivery systems and therefore delivery of a corrective or lethal gene to every cell in a solid tumor is problematic. Several laboratories are attempting to overcome this obstacle by developing better delivery systems and engineering viruses that selectively replicate in tumor tissue. [1] [2] [3] Another approach is to harness the power of apoptosis inducing genes so they induce collateral programmed cell death (PCD) in more than one cell (termed the ''bystander effect''). This would allow the use of safer, replicationincompetent vectors, and obviate the need to infect every cell within a tumor.
Fas ligand (FasL) (CD95L/APO-1L) is a 40 kDa type II membrane protein belonging to the tumor necrosis factor (TNF) family of proteins. 4 It binds to the Fas (CD95 or APO-1) 5, 6 receptor and initiates an apoptotic signal in Fas-sensitive cells. Previously, we demonstrated that a GFP-FasL fusion protein encoded by AdGFPFasL TET was capable of inducing Fas-mediated apoptosis in a panel of Fas-expressing prostate cancer (PCa) cells. 7, 8 However, it was unclear if AdGFPFasL TET -induced cell death was exclusively autocrine or if AdGFPFasL TETinfected cells also induced bystander killing in uninfected neighboring cells.
The purpose of the present study was to test the hypothesis that AdGFPFasL TET -infected PCa cells can induce bystander killing and that the mechanism involves Fas/FasL interaction. We demonstrate that AdGFPFasL TET -infected PPC-1 and DU145 cells release apoptotic bodies and cellular debris that contain GFP-FasL and can induce bystander killing in PPC-1 and PC-3 target cells, but not in DU145 cells. This bystander killing mechanism is Fas/FasL-dependent because it can be blocked by a pan spectrum caspase inhibitor Z-VAD-FMK or Fas neutralizing antibody ZB-4. We believe that this new understanding of FasL and its role in bystander activity will facilitate development of FasL as a PCa gene therapy.
Materials and methods

Cell lines
PC-3 and DU145 cells were purchased from ATCC (Rockville, MD). Jurkat and K-562 cells were obtained from Dr Yusuf Hannun (Medical University of South Carolina, Charleston, SC). PPC-1 cells were obtained from Dr Yi Lu at the University of Tennessee (Memphis, TN). Cell lines were maintained in complete medium (RPMI-1640 (GibcoBRL, Rockville, MD) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT)). Cells were passaged bi-weekly and maintained at 371C in the presence of 5% CO 2 .
Reagents
Construction of the adenoviral vectors AdCMVGFP and AdGFPFasL TET has previously been described. 7 Recombinant human-soluble FasL (rhsFasL) was obtained from Alexis Biochemicals (San Diego, CA). The anti-Fas blocking antibody ZB-4 was purchased from Kamiya Biomedical (Seattle, WA). The anti-Fas agonistic antibody CH-11 was purchased from Upstate Biotechnology (Lake Placid, NY). The pan spectrum caspase inhibitor Z-VAD-FMK (Z-Val-Ala-Asp(OCH 3 )-fluoromethylketone) was purchased from BIOMOL (Plymouth Meeting, PA). The adenovirus antifiber knob antibody 1D6.14 was obtained from Joanne Douglas at the University of Alabama, Birmingham. 1D6.14 was purified from mouse ascites fluid using the ImmunoPure IgG (Protein A) Purification Kit (Pierce, Rockford, IL) according to the manufacturer's instructions. The equilibration buffer used to elute this antibody was 1 Â phosphate buffered saline (PBS). Purified mouse IgG 2a (BD Biosciences, San Diego, CA) was used as an isotype control for 1D6.14. Purified mouse IgG 1 isotype (BD Biosciences) was used as a control for ZB4.
CH-11 and rhsFasL MTS assay
Cells (1 Â 10 4 ) were seeded and coincubated with 1 mg/ml CH-11 or rhsFasL plus 1 mg/ml enhancer in 96-well plates. After 24 hours, the MTS assay (Promega, Madison, WI) was used to quantitate cell death according to the manufacturer's protocol. Percent cytotoxicity was calculated using the formula: [1À(OD 490 treated wells/OD 490 control wells)] Â 100%. S1 and P1 preparation DU145 and PPC-1 cells (2 Â 10 7 ) were infected with AdCMVGFP or AdGFPFasL TET (multiplicity of infection (MOI) 50 for PPC-1 and MOI 70 for DU145) in a final volume of 14 ml in 150 mm tissue culture dishes. Uninfected cells were used as a control. After 24 hours, the culture medium (which contained floating debris and apoptotic bodies) was harvested and centrifuged at 2000 g for 10 minutes. Following centrifugation, the soluble fraction (S1) was aliquoted and stored at À801C. The pellet fraction (P1) was washed twice with complete medium, resuspended in 12 ml of complete medium, aliquoted, and stored at À801C.
Microscopic visualization of apoptotic bodies and cellular debris
PPC-1 cells (1 Â 10 6 ) were infected with AdGFPFasL TET and AdCMVGFP (MOI 50) and seeded into T-25 flasks in a final volume of 5 ml. After 18 hours, the supernatants were harvested, transferred to a 15 ml conical tube, and allowed to settle for 1.5 hours at 241C. The uppermost 500 ml was carefully removed, centrifuged at 2000 g for 10 minutes, and the resulting pellet resuspended in 20 ml of medium. Samples were placed on a slide, cover slipped, and viewed under Â 200 magnification.
P1T preparation
In contrast to the P1 fraction above, the P1T fraction was made from apoptotic bodies, floating debris, and the remaining adherent cells. Following removal of the apoptotic bodies and cellular debris as described above for P1, the remaining adherent cells were washed once with PBS and lifted using a trypsin-free chelating solution (described previously). 7 Both the wash and the lifted cells were pooled with the apoptotic bodies and floating debris, and the samples were centrifuged at 2000 g for 10 minutes. The resulting pellet (pellet 1 total or P1T) was resuspended in 12 ml of complete medium, aliquoted, and stored at À801C.
Determining viral titer
GFP expression was used to quantitate adenoviral titers. Serial dilutions of stock adenovirus, S1, or P1 (in triplicate) were coincubated with 293CrmA cells 9 for 48 hours in 96-well plates. The number of GFP-expressing 293CrmA cells per dilution was counted using UV fluorescence and the titer expressed as infectious units (IU)/ml.
S1 and P1 MTS assay
Target cells (1 Â 10 4 ) were seeded and coincubated with various volumes of S1 in 96-well plates, and complete medium was used to bring the final volume to 100 ml. For the S1 experiments, S1 was pretreated for 1 hour at 251C with 26 ng/ul of the antifiber knob neutralizing antibody 1D6.14, and then further incubated with target cells and 5 mg/ml doxycycline 9 for an additional 24 hours. S1 control wells contained S1 prepared from uninfected cells as well as doxycycline and 1D6.14. The MTS assay was used to quantitate cell death according to the manufacturer's instructions. For S1 samples percent cytotoxicity was calculated using the formula: [1-(OD 490 of S1 from infected cells/OD 490 of S1 control)] Â 100%. P1 experiments were performed similarly in 96-well plates. P1 control wells contained P1 from uninfected cells as well as the small amount of AdGFPFasL TET found to be present via titration (above). Again, after 24 hours the MTS assay was used to quantitate cell death. For the P1 samples percent cytotoxicity was calculated using the formula: [1À(OD 490 of P1 from infected cells/OD 490 of P1 control)] Â 100%. In Figure 3 (inset), Jurkat target cells were pretreated for 1 hour with 1.5 mg/ml ZB-4 (or IgG 1 isotype in the control) prior to S1 addition. In Figure 6 , the target cells were pretreated with 100 mM Z-VAD-FMK (dimethyl sulfoxide vehicle was used in the control) or 1.5 mg/ml ZB4 (IgG 1 isotype was used in the control), respectively, for 1 hour, and then challenged with either P1 generated from AdGFPFasL TET -infected DU145 cells or untreated DU145 cells plus AdGFPFasL TET as a control.
FACS analysis of P1-target cell interaction
Target cells (1 Â 10 5 ) were detached using a trypsin-free chelating solution and incubated on a rocker at 371C with 350 ml of GFPFasL P1 prepared from AdGFPFasL TETinfected cells, or P1 prepared from untreated cells plus the small amount of AdGFPFasL TET found to be present via titration (final volume 1 ml). After 1.5 hours, samples were gently vortexed 45 seconds and analyzed for P1-target cell interaction using a Becton-Dickinson FACSCalilbur cell sorter.
P1T cell death quantitation
Various ratios of P1T (effector):target cells were used to quantitate P1T bystander killing activity. Each microliter of P1T contained apoptotic bodies, cellular debris, and adherent cells generated from 1667 cells initially infected with AdGFPFasL TET . P1T was preincubated for 1 hour at room temperature with 19 ng/ml 1D6.14 and then coincubated with PPC-1 target cells (1 Â 10 4 ) in the presence of 5 mg/ml doxycycline for 24 hours in 96-well plates. Target cells were detached using a trypsin-free chelating solution to prevent Fas cleavage. To determine the number of viable target cells, wells were incubated with 0.015% trypan blue for 2 hours and viable cells (those excluding trypan blue) were counted using a gridded eyepiece (Olympus, WHK 10X/20L-H) under Â 100 magnification. Viable cells from four independent fields (1 Â 10 À4 cm 2 /field) were counted and used to calculate the total number of viable cells per well.
Statistical analysis
A two-tailed, unpaired t-test was used to determine statistical significance. Data were considered of statistical significance when the P-value o.01.
Results
Determining Fas sensitivity in prostate cancer cells
In a previous report, we screened a panel of PCa cell lines for Fas sensitivity using the exogenous Fas agonist CH-11 (an IgM monoclonal antibody). Our findings indicated that PPC-1 cells were moderately sensitive (29.272.3% cytotoxicity) to CH-11 (500 ng/ml) while DU145 and PC-3 cells were found to be essentially resistant (6.0710.4 and 1.372.3% cytotoxicity, respectively). 7 To better understand the Fas sensitivity profiles in these cell lines, experiments were repeated using higher concentrations of CH-11 (up to 1000 ng/ml), and additional experiments used recombinant human FasL (rhsFasL, up to 1000 ng/ ml) plus 1000 ng/ml enhancer. The rhsFasL protein consisted of the extracellular domain of human FasL (sFasL, aa 103-281) fused at the N-terminus to a linker peptide (26 aa) and a FLAG-tag. The enhancer was used to cross-link rhsFasL, thereby maximizing its killing activity. Jurkat cells were used as a positive control, and K-562 cells (which lack the Fas receptor) were used as a negative control. 7 Increasing the CH-11 concentration to 1000 ng/ml had only a minimal effect on these cell lines (Fig 1a) ; the most noteworthy response was seen in PC-3 cells that were slightly more sensitive at concentrations X500 ng/ml, that is, 1671.0% cytotoxicity was observed using 1000 ng/ml. Using rhsFasL plus enhancer had minimal effect on PC-3 cells (8.2710.3%) and DU145 cells (À13.172.7%), but increased cell killing in PPC-1 cells to 4972.9% (Fig 1b) . These data indicated that rhsFasL plus enhancer is a better Fas agonist than CH-11 in PPC-1 cells, and also demonstrated that PC-3 and DU145 cells remain essentially resistant to both types of exogenously applied Fas stimuli.
AdGFPFasL TET -infected PPC-1 and DU145 cells elicit bystander killing in uninfected neighboring cells
Previously, we demonstrated that an FasL expressing adenovirus (AdGFPFasL TET ) initiated significant Fas-mediated apoptosis in both Fas-resistant and Fassensitive PCa cells. 7 Looking at these AdGFPFasL TETinfected cells more closely, we observed the release of apoptotic bodies and cellular debris into the local environment (Fig 2) . We hypothesized that this apoptotic material was capable of inducing PCD in uninfected neighboring PCa cells, that is, a bystander effect. To test this hypothesis, PPC-1 and DU145 cells were infected using AdGFPFasL TET (MOI 50 for PPC-1 and 70 for DU145) and after 24 hours the culture medium was harvested, centrifuged at 2000 Â g, and separated into two fractions: supernatant (S1) and pellet (P1). Presumably, the S1 fraction contained small, soluble apoptotic bodies (undetectable by light microscopy), and soluble FasL (sFasL) generated by matrix metalloproteinase cleavage of mFasL at amino acid 126/127 in the extracellular domain. 10 We were concerned that the S1 and P1 fractions also contained adenovirus carryover, which would interfere with the analysis of bystander killing. To approximate the quantity of adenovirus carryover, the S1 and P1 fractions were titered via GFP fluorescence as described in Materials and methods. The DU145 generated S1 and P1 fractions contained 54 and 4.4% (expressed as percent of total) adenovirus carryover, respectively. The PPC-1 generated S1 and P1 fractions contained 32 and 6.5% adenovirus carryover, respectively. It should be noted that these P1 titers were undoubtedly overestimated because GFP-fluorescent debris was present in the P1 material prior to tittering. Despite this overestimation, we normalized for adenovirus carryover by including the appropriate MOI of adenovirus in the untreated P1 controls. In contrast to P1, S1 contained a high level of adenovirus carryover and therefore it was necessary to perform an adenovirus neutralization step. This was accomplished by preincubating the S1 fraction with an antifiber knob antibody (1D6.14) that has previously been shown to inhibit adenoviral infection by binding to the fiber knob and inhibiting attachment to the Coxsackie Adenovirus Receptor (CAR). 11 In addition, the S1 experiments were performed in the presence of 5 mg/ml doxycycline (Dox), which has previously been shown to inhibit GFPFasL transgene expression following AdGFPFasL TET (9) . Incubating AdGFPFasL TET (using the MOI found in 35 ml of FasL-mediated bystander effect analysis in PCa cells ML Hyer et al S1), S1 generated from untreated cells, and 1D6.14 at 251C for 60 minutes, and coculturing the target cells in the presence of Dox completely inhibited AdGFPFasL TETinduced PCa cell death (data not shown), allowing us to unequivocally analyze bystander killing.
To assay for bystander killing, target cells (PPC-1, PC-3, DU145, Jurkat, K-562) were incubated with increasing volumes of P1 and S1, and analyzed for cell death at 24 hours using the MTS assay. P1 generated from AdGFPFasL TET -infected DU145 and PPC-1 cells induced dose-dependent cell death in PPC-1, PC-3, and Jurkat cells (Fig 3a, b) (7) cells. The PPC-1-and DU145-generated S1 fractions did not induce cytotoxicity in any of the PCa cells; however, S1 induced apoptosis in Fas-sensitive Jurkat cells (Fig 3c, d) , which was inhibited by pretreating Jurkat cells with an Fas-neutralizing antibody (ZB-4). These data suggest that the S1 fraction contains sFasL and/or small, membrane bound FasL-containing apoptotic bodies sufficiently concentrated enough to kill Jurkat cells but not PCa cells. No apoptosis was observed using the highest volume (35 ml/well) of control P1 (generated from AdCMVGFP infected cells , Fig 3a, b) or control S1 (S1 control data not shown).
The P1 bystander killing mechanism is mediated through Fas
We hypothesized that the P1 bystander killing mechanism was mediated through Fas present on the surface of target cells. Previously, we demonstrated that PPC-1, DU145, and PC-3 target cells express cell surface Fas and that AdGFPFasL TET infected PCa cells produce the GFPFasL fusion protein. 7 To determine if AdGFPFasL TET -generated P1 and target cell interaction occurred, target cells were coincubated with P1 material and after 24 hours examined using light and fluorescent microscopy. Since FasL was fused to the GFP reporter, GFP fluorescence was used to track the GFPFasL fusion protein's location within P1. These coincubation experiments demonstrated that P1 and target cell interaction occurred, albeit with different affinities (Fig 4a) . Figure 3 Qualitative analysis of the bystander effect in different target cells using the P1 and S1 fractions. Target cells were incubated with increasing volumes of PPC-1 (a) and DU145 (b) generated P1 (nonfilled symbols) and assayed for cell death at 24 hours using the MTS assay. Assays were performed in 96-well plates in a final volume of 100 ml. As a control, 35 ml of AdCMVGFP P1 was used (filled symbols). Target cells are indicated as follows: Jurkat (diamond), PPC-1 (circle), PC-3 (triangle), DU145 (square), and K-562 (plus-square). S1 (35 ml) generated from PPC-1 (C) and DU145 (D) cells failed to induce cell death in PC-3 and PPC-1 target cells, but did induce cell death in Jurkat cells. Cell death observed in Jurkat cells was significantly inhibited by pretreating the cells with the Fas blocking antibody ZB-4 (see insets, *Po.01). Percent cytotoxicity was calculated as described in Materials and methods. Data shown indicate mean7SD (n ¼ 3) from one of three independent experiments.
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quantitate P1-target cell interaction by determining the number of target cells binding GFPFasL fluorescent material (Fig 4b, Table 1 ). The P1 material generated from both PPC-1 and DU145 cells had a higher affinity for PC-3 and PPC-1 target cells compared to DU145 cells. The relative level of P1-target cell binding correlated with the sensitivity to P1 bystander killing, that is, DU145 cells were resistant to P1 killing and displayed the lowest level of P1 binding. In the controls, that is, P1 generated from AdCMVGFP and uninfected cells, no apoptotic debris was observed; therefore no P1 and target cell binding was detected (data not shown).
We hypothesized that the P1 bystander killing mechanism was mediated through Fas/FasL interaction. To test this hypothesis, target cells were pretreated with the pan spectrum caspase inhibitor Z-VAD-FMK (100 mM) or the Fas neutralizing antibody ZB-4 (1.5 mg/ml), respectively, for 1 hour and then challenged with P1 (12-20 ml depending on the target cell). The MTS assay was used to quantitate cell death at 24 hours. Both the caspase inhibitor and the Fas neutralizing antibody blocked P1 bystander killing (Fig 5) , indicating that the P1 killing mechanism is both caspase-dependent and mediated through Fas/FasL interaction at the cell's surface.
To determine if P1 and target cell binding (as indicated in Fig 4 and Table 1 ) was dependent on Fas/FasL interaction, we attempted to block P1 and target cell binding using a Fas neutralizing antibody (ZB4). Target Figure 4 Qualitative and quantitative analysis of P1 aggregation onto PCa cells. (A) Phase and fluorescent microscopy were used to demonstrate that PPC-1 generated P1 aggregates minimally around DU145 target cells and maximally around PPC-1 target cells. Images (same field, Â 100 magnification) were taken 24 hours after incubating P1 (35 ml) and (1 Â 10 4 ) target cells in a final volume of 100 ml in a 96-well plate. P1 contains the GFPFasL fusion protein and therefore is visible under UV illumination. PPC-1 target cells were pretreated with 100 mM Z-VAD-FMK to inhibit P1-induced cell death. Arrows indicate examples of P1/target cell aggregation. (B) FACS analysis was used to quantitate the number of target cells that bind P1. Shown here is an example where PPC-1-generated P1 and PPC-1 target cells were used. The P1 only treatment (a) was used to set the R1 gate and exclude unbound P1 from the analysis. This R1 gate was applied to samples b-d (only events falling within R1 are shown in the right column). Untreated PPC-1 target cells (b) were used to set the R2 gate and any events falling within R2 were considered GFP positive. Panel (c) indicates the percent of target cells binding GFPFasL P1. As a control (d), untreated P1 from uninfected cells plus the appropriate MOI of AdGFPFasL TET was used and minimal GFPFasL expression (2.33%) was detected. cells were pretreated with 1.5 mg/ml of ZB4 and then incubated with P1 as described above. FACS analysis was used to quantitate the level of P1 and target cell binding. No inhibition of P1 binding was observed using the Fas neutralizing antibody (data not shown) suggesting that P1 binding to target cells was Fas/FasL independent.
Quantifying the bystander effect using P1T
We had used P1 to demonstrate bystander killing in PC-3, PPC-1 and DU145 cells (Fig 2) . Using P1 in this context was adequate for a qualitative analysis of the bystander effect. However, in order to accurately quantitate the bystander killing effect we needed to include in the analysis not only the floating apoptotic bodies and cellular debris in P1, but also the 25-50% of cells (in the total cell population) that remained attached to the tissue culture dish during P1 harvest. This adherent cell population was confirmed to be GFPFasL-expressing (using UV microscopy) and likely possessed bystander killing potential as suggested by Hedlund et al. 12 These adherent cells were included in the analysis of the bystander effect by detaching them with a trypsin-free chelating solution (to prevent mFasL cleavage) and pooling them with the P1 fraction; the resulting fraction was called P1 total (P1T). To neutralize adenoviral carryover (which would induce target cell apoptosis and make bystander analysis difficult), P1T fractions were incubated with the antifiber knob antibody (1D6.14) prior to use, and, in addition, target cells were cultured in the presence of 5 mg/ml Dox. To demonstrate that 1D6.14 and 5 mg/ml Dox inhibit AdGFPFasL TET -induced cell death, untreated (Unt) P1T cellular debris was incubated with high MOI (250) AdGFPFasL TET and 19 ng/ml 1D6.14 for 60 minutes at 251C prior to the addition of 1 Â 10 4 PPC-1 target cells and Dox. An MOI of 250 was selected because it represents the maximal possible amount of adenoviral carryover in 30 ml P1T. As shown in Figure 6a , 1D6.14 and Dox completely inhibited AdGFPFasL TET -induced cell death, thus allowing analysis of the bystander effect.
Using PPC-1 generated P1T as the effector material, different ratios of effector material and 1 Â 10 4 PPC-1 target cells were coincubated in 96-well plates for 24 hours, and the amount of bystander killing was calculated after adding trypan blue and counting the number of viable cells/well. Figure 6b shows that PPC-1 target cell death is nearly maximal using a ratio of 1 target cell to 1 effector cell.
Discussion
Previously, we demonstrated that a GFPFasL-expressing adenovirus (AdGFPFasL TET ) could induce Fas-mediated apoptosis in a panel of PCa cell lines (including PC-3, PPC-1, and DU145) despite resistance (in some cell lines) to the agonistic Fas antibody CH-11. 7 This work Target cells and P1 were incubated for 1.5 hours and then analyzed using FACS analysis (see the legend in Figure 4b for experimental set up). Percentages have been normalized to P1 generated from untreated cells plus the appropriate MOI of AdGFPFasL TET , that is, see Figure 4d . demonstrated that the Fas-mediated apoptotic pathway was intact in seemingly Fas-resistance cells, by using a GFPFasL transgene that was delivered intracellularly and expressed at high levels.
Our current results demonstrate that AdGFPFasL TETinfected PCa cells release apoptotic bodies and cellular debris (P1) that induce bystander killing in PC-3 and PPC-1 target cells, but not in DU145 cells. The bystander killing mechanism appears to be Fas/FasL-dependent because it can be blocked by pretreating the target cells with Fas neutralizing antibody or pan spectrum caspase inhibitor. The data suggest that mFasL (likely the predominant form of FasL expressed in P1 and P1T) is a more potent bystander killer compared to sFasL (likely the predominant FasL form in S1).
DU145 cells are particularly interesting because they are resistant to all forms of exogenous Fas stimuli (P1, S1, rhsFasL plus enhancer, and CH-11) yet are sensitive to Fas-mediated cell death when FasL is expressed intracellularly using AdGFPFasL TET 7 . In DU145 cells, AdGFPFasL TET treatment activates the classic Fasmediated apoptotic pathway involving activation or cleavage of caspase-8, -3, -7, -9, BID, PARP, and release of cytochrome c from mitochondria. 8 We believe that the mechanism by which AdGFPFasL TET overcomes Fasresistance in DU145 cells involves shifting the balance from a less apoptotic phenotype to a more favorable, proapoptotic phenotype. This can be accomplished, in part, by downregulating the antiapoptotic protein c-FLIP 8 and increasing the potential for death-inducing signaling complexes (DISC) formation by upregulating the number of cell surface Fas receptors (unpublished data), both of which occur following AdGFPFasL TET treatment. The lack of P1 bystander killing in DU145 cells suggest that each cell needs to be infected with AdGFPFasL TET to achieve these intracellular changes that eventually lead to cell death. We observed that DU145 target cells bind P1 less efficiently than PC-3 and PPC-1 target cells (Table 1) . It is possible that DU145 cells have reduced intracellular adhesion molecules (ICAM), which may be necessary to maximize Fas/FasL interactions between P1 and the target cells. It has been shown in an activated T-cell/target cell model system that Fasmediated apoptosis is dependent on cell-cell interaction forces and that neutralizing antibodies directed specifically against ICAM were effective at inhibiting the FasLmediated cytotoxicity of T cells. 13 Bystander Fas-mediated apoptosis may have relevance in other cancer gene therapy strategies. HSVtk/GCV, 14, 15 HSVtk/GCV plus IL-12, 16 and p53 17 have been shown to activate the Fas-mediated apoptotic death pathway. However, it is important to note that these observations may be cell-line dependent because other reports indicate that p53 and HSVtk/GCV utilize non-Fas-mediated apoptotic death pathways as well. 17, 18 In summary, the data presented in this paper demonstrate that AdGFPFasL TET infection induces bystander killing in certain PCa cell lines through an Fas-mediated mechanism. Currently, we are evaluating the use of FasL as gene therapy in animal models. These studies will help answer the following questions: (1) will AdGFPFasL TET reduce tumor burden in vivo? (2) does AdGFPFasL TET induce bystander killing inside and around the tumor? (3) how does the hosts' immune system, that is, tumor infiltrating lymphocytes and macrophages, interact with tumor cells expressing FasL? Regarding safety, we have injected 5 Â 10 9 IU of AdGFPFasL TET directly into xenograft tumors in both nude and syngeneic mouse models of prostate cancer and found this dose to be well tolerated (data not shown) with no observed side effects in any animal treated to date. These observations suggest that apoptotic material presenting FasL likely remains localized at the tumor site. Further, we have developed a series of adenoviruses with tissue-restricted expression of FasL 19 and Bax 20 and demonstrated they can be systemically administered to nude mice without any observable consequences to the liver.
In conclusion, this paper has demonstrated that apoptotic vesicles and cellular debris continue to transmit an apoptotic death signal via the Fas receptor and with some degree of potency, that is, death of one cell is sufficient to induce death of at least one additional cell. These encouraging results suggest that FasL should continue to be developed as a therapeutic for localized PCa and that the problem of delivery, common to most cancer gene therapy protocols, might be ameliorated by bystander activity associated with apoptotic vesicles from virally infected cells. Studies to directly address this question are ongoing. ) were incubated with 100 mM Z-VAD-FMK or 1.5 mg/ml ZB4 for 1 hour at 251C and then challenged with the indicated volumes of DU145-generated P1. The volume of DU145 generated P1 used/1 Â 10 4 target cells in a final volume of 100 ml is indicated as follows: 12 ml/PPC-1 *Po.01, 15 ml/PC-3 **Po.01, 20 ml/Jurkat. Similar results were observed using PPC-1-generated P1 (data not shown). ) were incubated with the indicated ratios of P1T (1D6.14 and Dox were also present) for 24 hours as described in Materials and methods. Data have been normalized to cells only control (set at 100%) and each data point represents the mean7SD from three separate experiments.
